OpenAI-Backed Red Queen Bio Raises $36M for AI Antibody Drugs — SkimNews
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- Red Queen Bio raised $36 million to use artificial intelligence in designing antibody drugs against novel pathogens, with biosecurity as an explicit focus area.
- Red Queen Bio is backed by OpenAI and is building defenses for threats that include AI-enabled bioweapons, not just naturally occurring pathogens.
Why it matters: A $36M raise backed by OpenAI positions Red Queen Bio in the small but well-capitalized club of AI biosecurity firms building antibody shields before AI-engineered pathogens arrive, giving OpenAI a foothold in defensive biotech it does not otherwise own.
Ask SkimNews
